HRAS and neoplasm: Next, we examined the commonly used model of DMBA–TPA carcinogenesis, where a single subcarcinogenic dose of DMBA, which causes EC mutations primarily in hras (initiation), is followed by repeated applications of the inflammatory reagent TPA (promotion), which allows for the few mutated clones to expand and form tumours.